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Abstract
Endothelial progenitor cells (EPCs) can be isolated from human bone marrow or peripheral
blood and reportedly contribute to neovascularization. Aptamers are 40-120-mer nucleo-
tides that bind to a specific target molecule, as antibodies do. To utilize apatmers for isola-
tion of EPCs, in the present study, we successfully generated aptamers that recognize
human CD31, an endothelial cell marker. CD31 aptamers bound to human umbilical cord
blood-derived EPCs and showed specific interaction with human CD31, but not with mouse
CD31. However, CD31 aptamers showed non-specific interaction with CD31-negative
293FT cells and addition of polyanionic competitor dextran sulfate eliminated non-specific
interaction without affecting cell viability. From the mixture of EPCs and 293FT cells, CD31
aptamers successfully isolated EPCs with 97.6% purity and 94.2% yield, comparable to
those from antibody isolation. In addition, isolated EPCs were decoupled from CD31 apta-
mers with a brief treatment of high concentration dextran sulfate. EPCs isolated with CD31
aptamers and subsequently decoupled from CD31 aptamers were functional and enhanced
the restoration of blood flow when transplanted into a murine hindlimb ischemia model. In
this study, we demonstrated isolation of foreign material-free EPCs, which can be utilized
as a universal protocol in preparation of cells for therapeutic transplantation.
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Introduction
Nucleic acid aptamers are single-stranded oligonucleotides, typically 40-120-mers, and bind to
a specific target with high affinity, as antibodies do [1]. Aptamers can be screened from oligo-
nucleotide libraries by systematic evolution of ligands by exponential enrichment (SELEX) [2].
Aptamers have attracted attention in the field of clinical diagnosis and therapy because of the
several advantages over antibodies, including low immunogenicity, efficient entry into biologi-
cal compartments due to smaller size, bacterial contamination-free production, stability in
storage, easy and rapid production, and conjugation chemistries for attachment of dyes or
functional groups during synthesis [3]. The first aptamer drug was approved by the US Food
and Drug Administration in 2005, and many others are in clinical pipelines [4, 5].
Endothelial progenitor cells (EPCs) incorporate into foci of physiological or pathological
postnatal neovascularization [6]. EPCs were first isolated from adult peripheral blood and later
shown to derive from bone marrow and other tissues [7]. EPCs contribute to vascular regenera-
tion by direct incorporation into newly forming blood vessels or by secretion of pro-angiogenic
factors [8, 9]. The widely used EPC culture starts with peripheral blood- or bone marrow-
derived mononuclear cells in endothelial growth factor-supplemented media. The adherent
cells in culture exhibit certain endothelial characteristics, such as expression of endothelial line-
age markers, including CD31, migration toward angiogenic growth factor gradient, formation
of tube-like structures, and contribution to repair of ischemic tissues after in vivo transplanta-
tion [10–13]. Transplanting EPCs is expected to provide a novel therapeutic opportunity for
treatment of ischemic disease through functional contribution to formation of new vasculature,
and various clinical trials are now ongoing [6, 14, 15].
CD31, also known as PECAM-1, is a cell adhesion and signaling receptor highly expressed
in endothelial cells and to various degrees on several non-erythroid hematopoietic cells [16].
CD31 is a member of the Ig-superfamily and a type I transmembrane glycoprotein with six
extracellular Ig-like homology domains [17]. The major ligand for CD31 is CD31, a homophi-
lic interaction mediated by Ig-like domain 1 [18]. CD31 plays a role in mediating homotypic
adhesions between neighboring endothelial cells and adhesions of leukocytes on endothelial
cells during transendothelial migration [19, 20]. Recent studies have demonstrated that EPCs
could be isolated from mouse and human bone marrow and human peripheral blood with
CD31 antibodies [21, 22]. Isolated CD31-positive cells exhibited robust angiogenic and vascu-
logenic activity in vitro and promoted vascular repair in a hindlimb ischemia mouse model
when transplanted. These results demonstrated that CD31 is an excellent marker in isolation
of angiogenic and vasculogenic cells for therapeutic cell transplantation [23, 24].
For clinical application of EPCs, human cord blood can be used for isolation of EPCs; how-
ever, cord blood contained not only EPCs but also various other cell types, such as immune
cells and mesenchymal stem cells. Therefore, isolation of EPCs from other cell types within
cord blood could increase therapeutic efficacy and safety in treatment of ischemic diseases.
For isolation of clinically applicable EPCs, magnetic cell sorting using antibody-conjugated
microbeads is currently used [6, 25]. However, there is some limitation in clinical application
of the antibody-conjugated microbeads in patients with hypersensitivity to murine proteins or
iron dextran due to immunogenic problem of mouse antibodies and toxicity of iron dextran
microbeads [26, 27]. Therefore, it is necessary to develop new cell isolation methods for prepa-
ration of foreign material-free EPCs.
In this study, we identified three clones of CD31 aptamer that bound to EPCs expressing
CD31 on the surface. CD31 aptamers specifically recognized human CD31, and we established
a protocol for isolation of EPCs from cell mixture using CD31 aptamers with purity and effi-
ciency comparable to those of antibody isolation. In addition, we efficiently decoupled CD31
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aptamers from isolated EPCs, which is a step forward in preparation of cells for therapeutic
transplantation. EPCs isolated from cultured cord blood mononuclear cells (MNCs) with
CD31 aptamers improved blood flow and vascular function when transplanted into ischemic
mouse model. These results demonstrate a successful identification and application of CD31
aptamers for isolating functional EPCs in therapeutic application.
Materials and Methods
Materials
Trypsin-EDTA and Hank's Balanced Salt Solution (HBSS) were purchased from Invitrogen
(Carlsbad, CA). Dulbecco’s Modified Eagle medium (DMEM; LM001-05) and 1× phosphate
buffered saline (pH = 7.4) (LB001-02) were purchased fromWelgene (Daegu, South Korea).
FITC-CD31 antibody (555445), isotype cocktail-C (558659), 7-Aminoactinomycin D (7-AAD)
(51-68981-E), and streptavidin magnetic beads (11205D) were purchased from BD Bioscience
(San Jose, CA). LS columns (130-042-401) and anti-FITC microbeads (130-048-701) were pur-
chased fromMiltenyi Biotech (Bergisch Gladbach, Germany). CD31-Cy5 aptamers, CD31-bio-
tin aptamers, and scrambled epidermal growth factor receptor (EGFR)-FITC aptamers were
purchased from Aptamer Science Inc. (Pohang, South Korea). Dextran sulfate (DxSO4) was
purchased from American International Chemial Inc. (9011-18-1, Framingham, MA). Endo-
thelial cell basal medium-2 (CC-3156) and EGM-2MV BulletKit (CC-4147) were purchased
from Lonza Ltd (Basel, Switzerland). 293FT cells were purchased from American Type Culture
Collection. Fetal bovine serum was purchased from Gibco (Life Technologies) and penicillin-
streptomycin solution was from HyClone (GE Healthcare, Uppsala, Sweden). Rhodamine-
labeled lectin (Ulex europaeus agglutinin I, RL-1062) and mounting medium with DAPI
(H-1200) were purchased from Vector Laboratories (Burlingame, CA). Gelatin (G1303),
MgCl2 (M2670), BSA (A7946), and all other chemicals were purchased from Sigma-Aldrich
(St. Louis, MO).
Cell Culture
Human EPCs were isolated from human umbilical cord blood and collected in disposable ster-
ile pyrogen-free bags containing anticoagulant (Green Cross, Seoul, Korea). Written informed-
consent was obtained from all donors and the protocol was approved by the Institutional
Review Board of Pusan National University Hospital (Permit Number: H-1302-005-015).
MNCs were isolated from blood with Ficoll-Paque PLUS (17-1440-02, GE healthcare) as
described previously [13]. Cells were seeded on culture dishes coated with 0.1% gelatin and
maintained in EGM-2MV BulletKit. The medium was exchanged in 24 hours after the initial
plating for removal of non-adherent cells and was exchanged every day for the first week. Colo-
nies of EPCs appeared 7–10 days after the initial isolation. Non-adherent cells were removed,
and the adherent cells were trypsinized and replated at a density of 1×106 cells per well. Expres-
sion of EPC-specific cell surface markers, including CD34, CD31, CD133, c-kit, Flk1, CXCR4,
and CD144, was confirmed by flow cytometry analysis. Hematopoietic lineage markers such as
CD11b, CD14, and CD45 were not expressed in EPCs, supporting the commitment of EPCs to
the endothelial lineage. 293FT cells were cultured in high glucose (4.5 g/L) DMEM supple-
mented with 10% fetal bovine serum and 100 U/mL penicillin-streptomycin. All cells were
maintained at 37°C in a 5% CO2 atmosphere.
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Flow Cytometry Analysis
Aptamer stocks were prepared by dissolving dry pellet to be 20 μMwith sterile distilled water
and stored at -20°C. Aptamers were heated at 95°C for 5 minutes and cooled down at room
temperature for formation of the proper conformation before application. Fluorescent dye-
labeled aptamers were incubated with cells at room temperature for 15 minutes in 100 μL of
aptamer binding buffer (1× PBS containing 2% FBS, 5 mMMgCl2, 0.2mM DxSO4). The incu-
bated cells were washed once with 1 mL of aptamer binding buffer before further analysis.
Cells labeled with aptamers or antibodies were analyzed by BD FACSCanto II (BD Biosciences)
by counting 10,000 events. 7-AAD was added at a 1:100 dilution to distinguish live cells from
dead cells. Obtained fluorescence signals were analyzed using the FACSDiva (ver 6.1.3, BD Bio-
sciences) or the FlowJo (ver 10, Tree Star Inc.).
Differentiation and Isolation of CD31-positive Cells from Mouse
Embryonic Stem Cells
Ainv15 mouse embryonic stem cells (ESCs) were cultured on mitomycin-C-treated mouse
embryonic fibroblasts in ESC culture media consisting of DMEM supplemented with 1× non-
essential amino acids, 1× GlutaMAX (35050–061, Life Technologies), 15% FBS, 1× penicillin-
streptomycin, 0.1 mM β-mercaptoethanol, and 1000 U/mL leukemia inhibitory factor
(ESG1106, Merck Millipore). Mouse embryonic fibroblasts were prepared as described previ-
ously [28] and maintained in mouse embryonic fibroblast culture medium (DMEM with high
glucose, 1× GlutaMAX, 10% FBS, and 1× penicillin-streptomycin). For hanging-drop culture
of EBs, dissociated ESCs were spotted on a petri-dish lid with 20 μL drops of cells (50,000 cells/
mL) in ES cell medium without leukemia inhibitory factor. Embryonic bodies were harvested
two days after hanging-drop formation, transferred to a petridish, and maintained on the
shaker in a humidified incubator at 37°C under 5% CO2 with change of media on day 4. EBs
were harvested on day 6 and subjected to analysis by flow cytometry.
Magnetic Cell Sorting of EPCs
The magnetic cell sorter (Miltenyi Biotec) was used for sorting cells with magnetic beads. Cells
were incubated with biotin-conjugated CD31 aptamers at room temperature or FITC-labeled
CD31 antibodies on ice in 100 μL of aptamer binding buffer for 15 minutes. Cells were washed
with 1 mL of aptamer binding buffer three times and incubated with streptavidin-magnetic
beads (120-000-287, Miltenyi Biotec) or anti-FITC magnetic beads (120-000-293, Miltenyi Bio-
tec) in 100 μL of aptamer binding buffer on ice for 20 minutes. After incubation, cells were
washed with 1 mL of aptamer binding buffer once and transferred to LS columns following the
company protocol. Briefly, LS column was placed in the magnet and pre-hydrated with 1 mL
of aptamer binding buffer. Cell-aptamer or antibody-magnetic bead complexes were resus-
pended in 500 mL aptamer binding buffer and applied to LS column, followed by washing with
1 mL aptamer binding buffer three times. LS column was removed from the magnet and cell-
aptamer or antibody-magnetic bead complexes were eluted with 1 mL of aptamer binding
buffer and plunger.
Decoupling of EPCs from CD31 Aptamer-EPC Complexes
EPCs bound with CD31-biotin aptamers and streptavidin magnetic-beads were incubated in
decoupling buffer (1× PBS containing 2% FBS, 5 mMMgCl2, 5 mM DxSO4) at 4°C for 15 min-
utes. After incubation, cells were applied to a magnetic cell sorter column pre-hydrated with 3
mL decoupling buffer. Pass-through fraction was collected to harvest decoupled EPCs, and
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residual cells in the column were collected as un-decoupled fraction. The decoupled EPCs were
centrifuged and washed with HBSS three times, and cells were then subjected to flow cytometry
analysis with CD31 antibodies for assessment of purity, and cell numbers were counted for
assessment of yield.
Cell Imaging
Cells on 0.1% gelatin coated cover slip were fixed with 4% paraformaldehyde in 1×PBS fol-
lowed by incubation in PBS containing 5% BSA and 0.5% triton X-100 (2052–6356, SHOWA,
Tokyo, Japan) at room temperature for 1 hour to limit non-specific binding. These specimens
were incubated with anti-CD31 antibodies (1:500 dilution) (ab28364, Abcam, Cambridge, UK)
or rhodamine-labeled lectin at 4°C overnight. After washing three times with PBS for 5 minute
individual incubation, CD31 antibody-incubated samples were further incubated with Alexa
Fluor 488-conjugated anti-rabbit antibody (1:200 dilution) (A-11008, Life Technologies) at
room temperature for 1 hour. For confocal imaging with aptamers, cells were co-incubated
with the biotin-labeled CD31 aptamers and Alexa Flour 488-conjugated streptavidin (S11223,
Life Technologies) at 37°C for 1 hour, fixed with paraformaldehyde, and washed three times.
The specimens were mounted in mounting medium with DAPI for visualization of nuclei. For
DiI-Ac-LDL labeling, cells on 0.1% gelatin coated cover slip in culture media were incubated
with DiI-Ac-LDL (1:20 dilution, BT902, Biochemical Technology, USA) for 4 hours at 37°C.
The specimens were fixed with 4% paraformaldehyde and finally washed with 1× PBS and
mounted with Vectashield medium (Vector Laboratories) containing 4',6-diamidino-2-pheny-
lindole (DAPI). Confocal microscope system (Olympus FluoView FV1000, Olympus Corp.,
Tokyo, Japan) was used for collection of images.
Mouse Hindlimb Ischemia Model and Blood Flow Measurement
This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was
approved by the Pusan National University Institutional Animal Use and Card Committee.
(Permit Number: PNU-2009-0033). All surgery was performed under sodium pentobarbital
anesthesia, and all efforts were made to minimize suffering. BALB/CA-nu/nu (male, age 8
weeks, weighing 18–20 g) were anesthetized with an intraperitoneal injection of 400 mg/kg
2,2,2-tribromoethanol for operative resection of one femoral artery. The femoral artery was
excised from its proximal origin as a branch of the external iliac artery to the distal point where
it bifurcates into the saphenous and popliteal arteries. After arterial ligation, HBSS or EPCs
(1×106 in 60 μl HBSS) were injected intramuscularly into three sites near ischemic injury
(20 μL/each site) with Hemilton syringe (1710, Reno Nevada, USA). The connective tissues of
the subcutis were closed with interrupted 6–0 polypropylene suture and the skin closed with
wound clips or 6–0 polypropylene suture. Post-surgery animals received subcutaneous injec-
tion of buprenorphine (0.03 mg/kg twice daily) for pain relief over 2 days, and meloxicam
solution (0.001 mg/g) was administered in the water for up to ten days post operatively to min-
imize any pain as a result of surgery. The health status of the mice was monitored once a day
for four weeks by observing changes in breathing pattern, overt pain or distress, locomotion
difficulties, proper food and water intake, and skin color. All mice used for data collection did
not show severe locomotion difficulties and consumed food and water properly. The extent of
necrosis was evaluated according to remained muscle and skin in mouse hindlimb. The scores
of necrosis were judged as follows; no necrosis on ischemic hindlimb is grade 0, grade I is lim-
ited necrosis of toe, grade II is necrosis progressed up to foot, grade III is up to ankle, grade IV
is up to knee. Blood flow of the ischemic and normal limb was measured using a laser Doppler
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perfusion imaging (LDPI) analyzer (Moor instruments, Devon, UK) on days 0, 7, 14, 21, and
28 after induction of hindlimb ischemia. Perfusion of the ischemic and non-ischemic limb was
calculated on the basis of colored histogram pixels. Red and blue colors indicate high and low
perfusion, respectively. Blood perfusion is expressed as the LDPI index representing the ratio
of ischemic versus non-ischemic limb blood flow. A ratio of 1 before surgery indicates equal
blood perfusion of both legs. Mice were sacrificed by euthanizing with carbon dioxide followed
by cervical dislocation on day 28 after surgery.
Immunostaining Analysis of Ischemic Limbs
For immunostaining of the tissue specimens, hindlimb muscles were removed and fixed with
acetone, methyl benzoate, xylene, and paraffin-embedded. Sections (6 μm in thickness) were
taken from the paraffin-embedded specimens at 150 μm intervals, stained with rat anti-CD31
antibody (H553373, BD Pharmingen). The specimens were incubated with Alexa Flour 488
goat anti-rat antibody (A-11006, Life Technologies), followed by washing and mounting in
Vectashield medium containing DAPI for visualization of nuclei. The stained sections were
visualized using laser scanning confocal microscopy (Olympus FluoView FV1000). Capillary
densities were assessed by counting the number of CD31-positive features per high power field
(×400). Three randomly-selected microscopic fields form three serial sections in each tissue
block were examined for capillary counting.
Results
Identification of CD31-specific Aptamers
In targeting distinct cells with functional cargo in complex mixtures of cells, aptamers can pro-
vide advantages over antibodies, which are most widely used in scientific and clinical applica-
tions, in the short generation time due to the entire chemical process and the easiness of
modification with functional groups [29]. Aptamers are generated through an in vitro process
termed SELEX, and a conservative estimate of the success rate is ~50% [30]. In addition, appli-
cation of in vitro selected aptamers to cells requires fine calibration. Among CD31 aptamer
clones selected using the purified extracellular domain of CD31, we tested three clones that
showed the highest affinity in the application of recognizing CD31 on the cell surface. EPCs
showed high expression of CD31 in analysis by flow cytometry using CD31 antibodies (S1 Fig).
In application of CD31 aptamers to EPCs at various concentrations (0.2, 2, 20, and 200 nM),
clones 1, 2, and 3 (AT-1, AT-2, and AT-3), each of which was labeled with Cy5, showed inter-
action with EPCs (Fig 1A). The intensity of the signal from CD31 aptamers continued to
increase from 0.2 to 200 nM, and 400 nM treatment did not further increase the signal intensity
(Fig 1A, data not shown). Among them, clone 1 (AT-1) showed the strongest signal, and we
proceeded with the rest of the experiments using CD31 aptamer clone 1, if not stated otherwise
(S1 Table). Incubation of ECPs with control scrambled EGFR-FITC aptamers did not generate
a positive signal (Fig 1B). These results suggest that we generated aptamers that recognize
CD31 on the surface of EPCs.
Resolving non-specific interaction of CD31 aptamers with dextran
sulfate
Although CD31 aptamers showed strong interaction with EPCs, the specificity of the interac-
tion was not confirmed. In flow cytometry analysis with CD31 antibodies, 293FT cells did not
show expression of CD31 (S1 Fig). When 293FT cells were incubated with CD31 aptamer
clone 1 at various concentrations from 0.2 to 200 nM, CD31 aptamers showed non-specific
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interaction with 293FT cells whereas control aptamers did not show interaction (Fig 2A). To
resolve the non-specific interaction of CD31 aptamers, we introduced dextran sulfate, which is
used for controlling hybridization temperature and blocking non-specific interaction in poly-
merase chain reaction, as an anionic competitor to incubation of CD31 aptamers with EPCs or
293FT cells [31, 32]. Without dextran sulfate, CD31 aptamers showed interaction with both
Fig 1. CD31 aptamers interact with human EPCs. (A) Flow cytometry analysis of EPCs after individual incubation with various concentrations (0, 0.2, 2,
20, and 200 nM) of three CD31 aptamer clones (AT-1, AT-2, and AT-3, Cy5-labeled) is shown. (B) Flow cytometry analysis of EPCs after incubation with
various concentrations (0, 0.2, 2, 20, and 200 nM) of control aptamers (FITC-labeled) is shown (n = 5).
doi:10.1371/journal.pone.0131785.g001
EPC Isolation with CD31 Aptamers
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Fig 2. Dextran sulfate effectively reduces the non-specific interaction of CD31 aptamers. (A) 293FT cells were incubated with various concentrations
(0, 0.2, 2, 20, and 200 nM) of CD31 aptamer clone 1 (AT-1, Cy5-labeled) or control aptamers (FITC-labeled) and subjected to flow cytometry analysis (n = 5).
(B) EPCs or 293FT cells were separately incubated with control aptamers (Ctrl AT, FITC-labeled) or CD31 aptamers (AT-1, Cy5-labeled, 200 nM) with or
without 0.2 mM dextran sulfate and subjected to flow cytometry. The overlap of histograms from 0 and 0.2 mM dextran sulfate experiments is shown (n = 5).
(C) The mixture of EPCs and 293FT cells was incubated with CD31 aptamers (AT-1, Cy5-labeled, 200 nM) and various concentrations (0, 0.2, 1, and 5 mM)
of dextran sulfate, followed by flow cytometry analysis (n = 3). (D) EPCs were incubated with CD31 antibodies (FITC-labeled) alone, CD31 aptamers alone
EPC Isolation with CD31 Aptamers
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EPCs and 293FT cells. Addition of 0.2 mM dextran sulfate did not inhibit the specific interac-
tion of CD31 aptamers with EPCs. However, the interaction of CD31 aptamers with 293FT
cells was completely abolished to the level of the control aptamers (Fig 2B). Incubation of
CD31 aptamers with the mixture of EPCs and 293FT cells without dextran sulfate did not dis-
tinguish two populations (Fig 2C). However, addition of 0.2 mM dextran sulfate to the mixture
of EPCs and 293FT cells clearly separated two peaks, indicating resolution of the non-specific
interaction. Higher concentrations of dextran sulfate, such as 1 and 5 mM, inhibited the spe-
cific interaction of CD31 aptamers, suggesting that 0.2 mM dextran sulfate is the optimal con-
centration for blocking the non-specific interaction but allowing the specific interaction. The
same patterns were observed with different clones of CD31 aptamers (S2 Fig). Single- or dou-
ble-staining of EPCs with CD31 antibodies and/or CD31 aptamers in the presence of 0.2 mM
dextran sulfate showed that CD31 aptamers are as efficient as CD31 antibodies in detecting
EPCs (Fig 2D). These results demonstrate that 0.2 mM dextran sulfate resolves the non-specific
interaction of CD31 aptamers and is required for application of CD31 aptamers in recognition
of EPCs.
Dextran, which is used in intravenous fluids, functions as a volume expander and in paren-
teral nutrition. Dextran, however, can apply osmotic pressure, and a certain molecular weight
of dextran sulfate sodium causes colitis in mice when added to drinking water [33]. Thus, we
tested whether dextran sulfate could have a deleterious effect on cell viability. When EPCs or
293FT cells were incubated with various concentrations (0, 0.2, 0.5, 1, or 2 mM) of dextran sul-
fate, neither EPCs nor 293FT cells showed differences in 7-AAD positivity when compared
with no treatment control (S3 Fig). To further confirm the effect of dextran sulfate on cell via-
bility, EPCs or 293FT cells were subjected to MTT assay. As shown in S3 Fig, incubation of
EPCs or 293FT cells with various concentrations (0, 0.2, 0.5, 1, or 2 mM) of dextran sulfate did
not change metabolic activity of cells. These results indicate that incubation of EPCs or 293FT
cells with 0.2 mM dextran sulfate for blocking the non-specific interaction of CD31 aptamers
does not affect cell viability.
To test species specificity of CD31 aptamers, we compared the interaction of CD31 apta-
mers with human EPCs and CD31-positive mouse cells, which was prepared from differentia-
tion of mouse ESCs into embryoid bodies. As shown in S4 Fig, day 6 mouse embryoid bodies
generated CD31-positive cells recognized by anti-mouse CD31 antibodies. However, neither
CD31 aptamers nor anti-human CD31 antibodies showed the interaction with CD31-positive
cells derived from mouse embryoid bodies. Taken together, these results demonstrate that we
generated CD31 aptamers specific to human CD31 and established a protocol for recognizing
EPCs from cell mixture without decreasing cell viability.
Visualizing EPCs using CD31 aptamers
We tested whether CD31 aptamers could be used in visualizing EPCs as antibodies in immuno-
cytochemistry. When EPCs or 293FT cells were plated separately, CD31 antibodies specifically
stained EPCs (Fig 3A). Following the immunocytochemistry protocol with aptamer binding
buffer, CD31 aptamers were applied to EPCs or 293FT cells. Without dextran sulfate, CD31
aptamers showed strong interaction with EPCs (Fig 3B). Low level interaction with 293FT cells
was also observed though low level interaction is weaker than that in flow cytometry analysis
probably due to increased washing in immunocytochemistry protocol. However, addition of
0.2 mM dextran sulfate eliminated non-specific interaction of CD31 aptamers with 293FT cells
(AT-1, Cy5-labeled, 200 nM), or with both CD31 antibodies and CD31 aptamers and subjected to flow cytometry analysis. Two-dimensional plots are shown
(n = 5).
doi:10.1371/journal.pone.0131785.g002
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but conserved the specific interaction with EPCs. These results demonstrate that CD31 apta-
mers can be used for visualizing EPCs with efficiency comparable to that of CD31 antibodies in
immunocytochemistry.
Isolating EPCs using CD31 aptamers
EPCs have been shown to provide therapeutic benefits when transplanted into ischemic injury
models [12, 34]. We tested whether CD31 aptamers could isolate EPCs from the mixture of
cells. We prepared, the cell mixture comprised of ~72% EPCs and ~28% 293FT cells (Fig 4A).
To test the efficiency of cell sorting with CD31 aptamers, the mixture of EPCs and 293FT cells
was subjected to magnetic bead sorting using biotin-labeled CD31 aptamers and streptavidin
magnetic beads. The mixture of EPCs and 293FT cells was also subjected to magnetic bead
sorting using CD31 antibodies for comparison of the sorting efficiency. In analysis of post-sort
fractions using CD31 antibodies, the EPC fraction isolated by CD31 antibodies showed 98.9%
purity and 99.5% yield. The EPC fraction isolated by CD31 aptamers showed 97.6% purity and
94.2% yield, comparable to those of isolation by CD31 antibodies (Fig 4B). When isolated
EPCs were subjected to culture, both EPC fractions from CD31 aptamer-isolation and CD31
antibody-isolation showed proliferating EPCs, whose morphology is distinct from that of
293FT cells (Fig 4C). These results demonstrate that CD31 aptamers can isolate EPCs with
high purity and high yield comparable to those of CD31 antibodies from the mixture of cells.
Fig 3. CD31 aptamers specifically stain EPCs for visualization with fluorescencemicroscopy. (A) EPCs or 293FT cells were stained with CD31
antibodies (Alexa Fluor 488-labeled) and DAPI (blue). Images were taken by confocal microscope (Olympus FluoView FV1000). (B) EPCs or 293FT cells
were stained with CD31 aptamers (AT-1, biotin-labeled, 400 nM) at 37°C for 1 h with or without 0.2 mM dextran sulfate, followed by staining with streptavidin-
Alexa Fluor 488 and DAPI (blue). Images were taken by confocal microscope (Olympus FluoView FV1000). Scale bar = 40 μm (n = 3).
doi:10.1371/journal.pone.0131785.g003
EPC Isolation with CD31 Aptamers
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Fig 4. CD31 aptamers isolate EPCs from themixture of EPCs and 293FT cells and EPCs are decoupled from CD31 aptamers. (A) EPCs, 293FT cells,
or the mixture of EPCs and 293FT cells were analyzed by flow cytometry after staining cells with FITC-labeled anti-human CD31 antibodies (n = 3). (B) The
mixture of EPCs and 293FT cells was subjected to magnetic bead sorting using CD31 aptamers (AT-1, biotin-labeled) (upper panel) or CD31 antibodies
(lower panel). (+) indicates the fraction with positive selection and (-) indicates the fraction with negative selection. Flow cytometry analysis of each fraction
with CD31 antibodies (FITC-labeled) after isolation is shown (n = 3). (C) Bright field images of cultured cells in (+) fraction after magnetic bead isolation of the
mixture of EPCs and 293FT cells with CD31 aptamers (upper panel) or CD31 antibodies (lower panel) are shown. Scale bar = 200 μm (n = 3). (D) Decoupling
of EPCs from CD31 aptamer-EPC complexes by treatment with DxSO4. EPCs were decoupled from the CD31 aptamer-EPC complexes and recovery yield
was calculated by comparing cell numbers before and after decoupling with DxSO4 (left panel) (n = 4). Flow cytometry analysis of decoupled cells with CD31
antibody is shown in the right panel. (E) Viability of EPCs before and after decoupling with DxSO4 is shown by flow cytometry analysis (n = 5).
doi:10.1371/journal.pone.0131785.g004
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Decoupling of CD31 aptamers from EPCs
The presence of foreign materials on the surface of cells intended for transplantation for thera-
peutic purposes is a cause for concern regarding decrease of efficacy related to immune reac-
tions. We tested decoupling of CD31 aptamers from EPCs after binding of CD31 aptmer to
EPCs. After incubation of EPCs with CD31 aptamers in the presence of 0.2 mM dextran sul-
fate, EPCs were subjected to magnetic bead isolation protocol to emulate purification process
without contaminating 293FT cells. EPCs were eluted from magnetic column and subsequently
subjected to a decoupling process in order to release EPCs from aptamers and magnetic beads.
Incubation of EPC-CD31 aptamer-magnetic bead complexes with decoupling buffer (aptamer
binding buffer containing 5 mM dextran sulfate) at 4°C for 15 minutes and passaging through
magnetic column showed .decoupling of EPCs from aptamer-magnetic bead complexes with
63.8% yield (Fig 4D). Decoupled EPCs maintained CD31 expression on the surface and did not
show a change in viability compared with that prior to decoupling (Fig 4D and 4E). These
results demonstrate that foreign material-free EPCs can be harvested from the isolation process
using CD31 aptamers and magnetic beads.
EPCs were established from the culture of MNCs from cord blood for more than three
weeks [12]. In two-week culture of cord blood MNCs, heterogeneous morphology of cells (Fig
5A) and existence of CD31-negative cells along with CD31-positive cells were observed (data
not shown). To expedite the establishment of EPCs in culture, we isolated CD31-positive cells
from two-week culture of cord blood MNCs with biotin-labled CD31 aptamers and streptavi-
din magnetic beads and decoupled CD31 aptamers to generate foreign material-free EPCs as
described in S5 Fig. CD31 aptamer-isolated and decoupled cells from cord blood MNC culture
generated homogeneous cells in the subsequent culture (Fig 5A). Flow cytometry analysis
showed CD31 aptamer-isolated and decoupled cells were positive for EPC surface markers
such as CD31 (99.7%), KDR (43.3%), and VE-cadherin (92.8%) (S6 Fig). CD31 aptamer-iso-
lated and decoupled cells in the culture showed endothelial characteristics such as uptake of
Ac-LDL and staining by lectin (Fig 5B and 5C). These results demonstrate that foreign mate-
rial-free EPCs can be isolated from heterogeneous mixture of cells using CD31 aptamers.
Neovascularization by the CD31 aptamer-isolated and decoupled EPCs
CD31-postive cells isolated from peripheral blood or bone marrow were previously shown to con-
tribute to the repair of ischemic vascular injuries [21, 22]. Therefore, we tested whether the foreign
material-free CD31-positive cells decoupled from CD31 aptamer-conjugated microbeads could
contribute to the vascular repair from ischemic injuries. Femoral artery of nude mice was ligated
surgically to introduce ischemic injuries and the foreign material-free CD31-positive cells were
injected intramuscularly to the site of ischemic injury on the following day (1 x 106 cells/injec-
tion). Mice were monitored up to day 28 after EPC injection with time-course measuring of blood
flow. Analysis of mice on day 28 showed that EPC injection significantly improved blood flow
and limb salvage compared with control HBSS injection (Fig 6A, 6B and 6C). Immunohistochem-
istry analysis of salvaged limbs showed that EPC injection increased CD31-positive capillaries
compared with control HBSS injection (Fig 6D and 6E). These results demonstrate that EPCs
established from heterogeneous culture of cord bloodMNCs using CD31 aptamer isolation and
decoupling protocol are functional and contribute to the recovery from ischemic injuries.
Discussion
Reliable targeting of cell surface molecules is an important task in isolation, visualization, or
delivery of drugs to the cells of interest. Thus far antibodies are the most widely used targeting
reagent with high affinity and specificity in biomedical applications [35]. Besides high binding
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affinity and specificity comparable to those of antibodies, aptamers provide advantages over
antibodies, including convenient synthesis and modifications, acceptable immunogenicity, and
rapid tissue penetration [36]. The short production time and the straightforward modification
and functionalization of aptamers make them suitable for attachment of functional groups in
order to visualize or direct drugs into the targeting cells [3]. Isolation of cells with a low immu-
nogenic reagent is favorable in transplanting cells into patients for therapeutic purposes [37,
38]. The rapid tissue penetration is beneficial in visualizing the target cells in vivo [1]. However,
application of aptamers to cells requires further adjustments as aptamers were selected for the
interaction with the purified proteins in vitro [39, 40]. In this study, we tested the aptamers
selected in vitro using the purified extracellular part of CD31 protein for application to cells
and established the protocols for detection, visualization, and isolation of EPCs, which provide
an advantage in preparation of cells for therapeutic transplantation.
We tested three clones of CD31 aptamer on EPCs and 293FT cells. Although all three clones
of the CD31 aptamer showed interaction with EPCs, they also showed non-specific interaction
with 293FT cells (Fig 2 and S2 Fig). Our aptamers are Slow Off-rate Modified Aptamers
(SOMAmers), which, like many nucleic acid drugs, may show non-specific and low-affinity
interaction with various proteins in the μM range [41, 42]. This suggests that aptamers should
be in the nM or better affinity range in order to show target-specific interaction. Our CD31
Fig 5. Preparation of foreignmaterial-free EPCs from human cord blood MNC culture by magnetic cell sorting isolation with CD31 aptamer and
decoupling processes. (A) Two-week culture of cord blood MNCs were subjected to magnetic bead isolation process with CD31 aptamers, followed by
decoupling from CD31 aptamers with decoupling buffer. Bright field images (high and low magnification) of the MNCs and the EPCs decoupled from CD31
aptamers are shown. Scale bar = 100 μm. (B, C) Endothelial characteristics of the EPCs decoupled from CD31 aptamers were determined by staining with
DiI-Ac-LDL (B) or lectin (Ulex europaeus agglutinin I) (C). Fluorescence images were taken by confocal microscope (Olympus FluoView FV1000). Scale
bar = 40 μm. Representative data from three independent experiments are shown.
doi:10.1371/journal.pone.0131785.g005
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Fig 6. Foreignmaterial-free EPCs enhance restoration of blood flow and limb salvage from ischemic injury. (A) The foreign material-free EPCs were
injected intramuscularly to injury site of nude mice with hindlimb ischemia (1×106 cells/injection). Representative images of mice with laser Doppler perfusion
imaging (LDPI) on day 0 and day 28 after injection with HBSS buffer (n = 6) or EPCs (n = 6) are shown. (B) Time-course quantitative analysis of blood flow by
LDPI of hindlimb ischemia-induced mice injected with EPCs or HBSS is shown. (C) Statistical analysis of necrosis score on day 28 is shown. (D)
Immunostaining of CD31-positive capillaries (green) in salvaged hindlimbs on day 28 after intramuscular injection of HBSS or EPCs is shown. (E)
Quantitative analysis of capillary density in salvaged limbs on day 28 by counting the number of CD31-positive capillaries per high-power field (HPF) is
shown. * indicates p < 0.05 vs HBSS by Student’s t-test (n = 6 for EPC and n = 6 for HBSS respectively).
doi:10.1371/journal.pone.0131785.g006
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aptamer clones have Kd values in the nM range (AT-1, 2.28 nM; AT-2, 3.36 nM; AT-3, 1.14
nM). To resolve non-specific interaction with non-cognate targets, we applied equilibrium and
kinetic challenges by addition of dextran sulfate as a polyanionic competitor and washing repeat-
edly, as previously reported [31, 32, 36]. In our fine tuning, 0.2 mM dextran sulfate eliminated
non-cognate interaction but did not diminish specific interaction. However, high concentrations
of dextran sulfate (1–2 mM) disrupted specific interaction with EPCs. In the case of EGFR apta-
mers, dextran sulfate was not necessary to show the specific interaction with cells but 1 mM dex-
tran sulfate was adopted in the purification of EGFR protein (data not shown) [31]. These
results suggest that individual optimization of aptamers in each application may be necessary in
order to reveal specific interaction over non-specific interaction with non-cognate targets.
The advantage of CD31 aptamers over CD31 antibodies is decoupling of aptamer from
EPCs after isolation (Figs 4D and 5). Efficiency of CD31 aptamers was as good as that of CD31
antibodies in isolating EPCs (Fig 4B). In transplanting EPCs for therapeutic purposes, the
absence of foreign material is preferred [15]. Isolation of EPCs using antibodies leaves a cause
for concern regarding transplanting EPCs with antibodies and magnetic beads attached to the
surface. In the development of therapeutic antibodies, the preference has shifted from mouse
monoclonal antibodies to chimeric antibodies, humanized antibodies and finally to human
antibodies in an effort to minimize the safety issue and diminished efficacy caused by immuno-
genicity of antibodies [43]. Even with human antibodies, immunogenicity concerns remain
due to diverse genotypes, different immunoglobulin G allotypes, and generation of anti-
idiotypic antibodies [26, 44]. Magnetic beads, when used in isolation of endothelial cells, were
shown to have a late detrimental effect on cell proliferation and metabolism [27]. Furthermore,
aptamers and oligonucleotides could activate Toll-like receptor pathway or generate antibodies
against them due to the presence of CpG motif [45, 46]. We developed a simple and universal
protocol for release of aptamers and magnetic beads from EPCs by a short-time treatment with
a high concentration of dextran sulfate after isolation of EPCs. In comparison, a common-
decoupling competitor of antibody-antigen interaction has not been reported [32, 47]. Our
simple protocol may provide a universal platform for isolation of foreign material-free target
cells, which is expected to enhance the efficacy in therapeutic cell transplantation.
Conclusion
In conclusion, we generated CD31 aptamers that specifically recognize human CD31 on the
cell surface and established a protocol for detection and visualization in flow cytometry and
fluorescence microscopy. Furthermore, we established a protocol for isolating foreign material-
free EPCs from heterogeneous mixture of cells using CD31 aptamers and magnetic beads. We
expect our results contribute to the expedition of recovery from ischemic conditions and clini-
cal applications of stem cells.
Supporting Information
S1 Fig. CD31 is expressed on EPCs but not on 293FT cells. Flow cytometry analysis of EPCs
(A) or 293FT (B) cells with FITC-labeled CD31 antibodies and isotype control antibodies is
shown (n = 5).
(TIF)
S2 Fig. Dextran sulfate resolves non-specific interaction of CD31 aptamers. The mixture of
EPCs and 293FT cells were incubated with CD31 aptamers (AT-2 and AT-3, Cy5-labeled) and var-
ious concentrations of dextran sulfate. Histogram from flow cytometry analysis is shown (n = 3).
(TIF)
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S3 Fig. No effects of dextran sulfate on cell viability. (A) Flow cytometry analysis with
7-AAD staining after incubation of EPCs or 293FT cells with various concentrations (0, 0.2,
0.5, 1, and 2 mM) of dextran sulfate at room temperature for 15 minutes (n = 5). (B) EPCs or
293FT cells were incubated with various concentrations (0, 0.2, 0.5, 1, and 2 mM) of dextran
sulfate at room temperature for 30 minutes and subjected to MTT assay (n = 4).
(TIF)
S4 Fig. Interaction of CD31 aptamers with human CD31 but not with mouse CD31. (A)
Mouse ESCs were differentiated into EBs and day 6 mouse EB-derived cells were subjected to
flow cytometry analysis with control isotype antibodies (left panels) or control scrambled
EGFR-FTIC aptamers (right panel). (B) Day 6 mouse EB-derived cells were subjected to flow
cytometry analysis with CD31 aptamers (AT-1, Cy5-labeled) in combination with FITC-
labeled anti-human CD31 antibodies (upper panels) or PE-labeled anti-mouse CD31 antibod-
ies (lower panels) (n = 3).
(TIF)
S5 Fig. Schematic description of EPC isolation with CD31 aptamers and decoupling from
CD31 aptamers is shown.
(TIF)
S6 Fig. Maintenance of EPC surface markers in foreign material-free EPCs. Flow cytometry
analysis of foreign material-free EPCs isolated from two-week cord blood MNC culture using
CD31 aptamers and decoupling protocol is shown (n = 4).
(TIF)
S1 Table. Aptamer sequences. 5-(N-naphthylcarboxyamide)-2’-deoxyuridine (NapdU) apt-
maers are shown. 6: dTTPs! dUTPs.
(TIF)
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